Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
PositiveTechnology

Novartis has announced its agreement to acquire Avidity Biosciences for $12 billion, a move that is set to enhance its portfolio of treatments for neuromuscle disorders. This acquisition is significant as it not only strengthens Novartis's position in the pharmaceutical industry but also promises to bring innovative therapies to patients suffering from these conditions.
— Curated by the World Pulse Now AI Editorial System

